These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29856192)

  • 61. An etiologic approach to management of duodenal and gastric ulcers.
    Rex DK
    J Fam Pract; 1994 Jan; 38(1):60-7. PubMed ID: 8289053
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of peptic ulcer disease not related to Helicobacter.
    Yeomans ND
    J Gastroenterol Hepatol; 2002 Apr; 17(4):488-94. PubMed ID: 11982732
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease.
    Tomita T; Fukuda Y; Tamura K; Tanaka J; Hida N; Kosaka T; Hori K; Sakagami T; Satomi M; Shimoyama T
    Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():204-9. PubMed ID: 11966543
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users.
    Dries AM; Richardson P; Cavazos J; Abraham NS
    Aliment Pharmacol Ther; 2009 Sep; 30(6):652-61. PubMed ID: 19573167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
    Gisbert JP; Piqué JM
    Med Clin (Barc); 2005 May; 124(18):697-709. PubMed ID: 15899166
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acid suppression therapy: where do we go from here?
    Scarpignato C; Pelosini I; Di Mario F
    Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
    Gyawali CP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Primary prevention of ulcers in patients taking aspirin or NSAIDs.
    Med Lett Drugs Ther; 2010 Mar; 52(1333):17-9. PubMed ID: 20300052
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Role of acid suppressants in prophylaxis of NSAID damage.
    Chan FK; Sung JJ
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):433-45. PubMed ID: 11403537
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan.
    Tsumura H; Tamura I; Tanaka H; Chinzei R; Ishida T; Masuda A; Shiomi H; Morita Y; Yoshida M; Kutsumi H; Inokuchi H; Doita M; Kurosaka M; Azuma T
    Intern Med; 2007; 46(13):927-31. PubMed ID: 17603228
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
    Lodato F; Azzaroli F; Di Girolamo M; Feletti V; Cecinato P; Lisotti A; Festi D; Roda E; Mazzella G
    World J Gastroenterol; 2008 May; 14(19):2980-5. PubMed ID: 18494046
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products].
    Therapie; 1999; 54(5):509-17. PubMed ID: 10667082
    [No Abstract]   [Full Text] [Related]  

  • 76. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease.
    Hatlebakk JG; Emken BE; Glazkov V; Hoff DA; Hausken T
    Tidsskr Nor Laegeforen; 2013 Jan; 133(1):43-6. PubMed ID: 23306993
    [No Abstract]   [Full Text] [Related]  

  • 77. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of Helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event.
    Hsiao FY; Tsai YW; Wen YW; Kuo KN; Tsai CR; Huang WF
    Pharmacotherapy; 2011 Mar; 31(3):239-47. PubMed ID: 21361733
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy.
    Cherian PT; Cherian S; Singh P
    Gastrointest Endosc; 2007 Sep; 66(3):491-7. PubMed ID: 17640640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
    Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
    Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.